Food and Drug Administration

Oncologic Drugs Advisory Committee

December 17, 2002


Bexxar® Tositumomab (Anti-B1) and Iodine131-Tositumomab


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Tositumomab Therapeutic Regimen, Dr. Terrye Zaremba, PhD, Corixa Corp. (HTM) (PPT)

Tositumomab Therapeutic Regimen (TTR), Dr. Litwin, FDA (HTM) (PPT)

Open Public Hearing

Abigail Alliance for Better Access to Developmental Drugs, Burroughs (HTM) (PPT)

Comments (PDF)